综述 |
|
|
|
|
大麻素1型受体正电子发射断层显像在神经精神疾病中的应用进展 |
马丽娟1,吴爽1,张凯2,田梅1,张宏1,3,4,*( ) |
1.浙江大学医学院附属第二医院核医学科 浙江大学医学PET中心 浙江省医学分子影像重点实验室 浙江大学核医学与分子影像研究所,浙江 杭州 310009 2.日本理化学研究所生命机能研究中心健康与病态科学研究室,日本 神户 650-0047 3.浙江大学生物医学工程教育部重点实验室,浙江 杭州 310027 4.浙江大学生物医学工程与仪器科学学院,浙江 杭州 310027 |
|
Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases |
MA Lijuan1,WU Shuang1,ZHANG Kai2,TIAN Mei1,ZHANG Hong1,3,4,*( ) |
1. Department of Nuclear Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University Medical PET Center, Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, Hangzhou 310009, China; 2. Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan; 3. Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou 310027, China; 4. College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou 310027, China |
引用本文:
马丽娟,吴爽,张凯,田梅,张宏. 大麻素1型受体正电子发射断层显像在神经精神疾病中的应用进展[J]. 浙江大学学报(医学版), 2021, 50(5): 666-673.
MA Lijuan,WU Shuang,ZHANG Kai,TIAN Mei,ZHANG Hong. Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases. J Zhejiang Univ (Med Sci), 2021, 50(5): 666-673.
链接本文:
https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2021-0063
或
https://www.zjujournals.com/med/CN/Y2021/V50/I5/666
|
1 |
HOUL, RONGJ, HAIDERA, et al.Positron emission tomography imaging of the endocannabinoid system: opportunities and challenges in radiotracer development[J]J Med Chem, 2021, 64( 1): 123-149.
doi: 10.1021/acs.jmedchem.0c01459
|
2 |
CRISTINOL, BISOGNOT, DI MARZOV. Cannabinoids and the expanded endocannabinoid system in neurological disorders[J]Nat Rev Neurol, 2020, 16( 1): 9-29.
doi: 10.1038/s41582-019-0284-z
|
3 |
IBARRA-LECUEI, PILAR-CUéLLARF, MUGURUZAC, et al.The endocannabinoid system in mental disorders: evidence from human brain studies[J]Biochem Pharmacol, 2018, 97-107.
doi: 10.1016/j.bcp.2018.07.009
|
4 |
张 宏. PET分子影像: 神经核医学发展的机遇与挑战[J]. 中华核医学与分子影像杂志, 2017, 37(9): 525-526 ZHANG Hong. PET molecular imaging: the opportunity and challenge for the development of neuro-nuclear medicine[J].Chinese Journal of Nuclear Medicine and Molecular Imaging, 2017, 37(9): 525-526. (in Chinese)
|
5 |
沈 灵, 华 甜, 刘志杰. 人源大麻素受体的结构生物学研究[J]. 自然杂志, 2021, 43(1): 25-31 SHEN Ling, HUA Tian, LIU Zhijie. Structural studies of human cannabinoid receptors[J]. Chinese Journal of Nature, 2021, 43(1): 25-31. (in Chinese)
|
6 |
HUAT, VEMURIK, PUM, et al.Crystal structure of the human cannabinoid receptor CB1[J]Cell, 2016, 167( 3): 750-762.e14.
doi: 10.1016/j.cell.2016.10.004
|
7 |
SHAOZ, YINJ, CHAPMANK, et al.High-resolution crystal structure of the human CB1 cannabinoid receptor[J]Nature, 2016, 540( 7634): 602-606.
doi: 10.1038/nature20613
|
8 |
HUAT, VEMURIK, NIKASS P, et al.Crystal structures of agonist-bound human cannabinoid receptor CB1[J]Nature, 2017, 547( 7664): 468-471.
doi: 10.1038/nature23272
|
9 |
HU S S, MACKIE K. Distribution of the endocannabinoid system in the central nervous system[J]. Handb Exp Pharmacol, 2015, 231: 59-93
|
10 |
华 甜. 人源大麻素受体亚型Ⅰ的结构和功能研究[D]. 北京: 中国科学院大学, 2017 HUA Tian. Structural and functional studies on the human cannabinoid receptor[D]. Beijing: University of Chinese Academy of Sciences, 2017. (in Chinese)
|
11 |
安永超, 任 维, 杨唐斌. 大麻素Ⅰ型受体生理调节作用研究进展[J]. 中国公共卫生, 2011, 27(7): 859-861 AN Yongchao, REN Wei, YANG Tangbin, Research progress on the physiological regulation of cannabinoid type Ⅰ receptors[J]. Chinese Journal of Public Health, 2011, 27(7): 859-861. (in Chinese)
|
12 |
PIAZZAP V, COTAD, MARSICANOG. The CB1 receptor as the cornerstone of exostasis[J]Neuron, 2017, 93( 6): 1252-1274.
doi: 10.1016/j.neuron.2017.02.002
|
13 |
BASAVARAJAPPAB S, SHIVAKUMARM, JOSHIV, et al.Endocannabinoid system in neurodegenerative disorders[J]J Neurochem, 2017, 142( 5): 624-648.
doi: 10.1111/jnc.14098
|
14 |
FRAGUAS-SáNCHEZA I, TORRES-SUáREZA I. Medical use of cannabinoids[J]Drugs, 2018, 78( 16): 1665-1703.
doi: 10.1007/s40265-018-0996-1
|
15 |
UDDINM S, MAMUNA A, SUMSUZZMAND M, et al.Emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in alzheimer’s disease[J]Front Pharmacol, 2020, 1097.
doi: 10.3389/fphar.2020.01097
|
16 |
ORSOLINIL, CHIAPPINIS, VOLPEU, et al.Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (ptsd): a systematic review[J]Medicina, 2019, 55( 9): 525.
doi: 10.3390/medicina55090525
|
17 |
MATHEWSW B, SCHEFFELU, FINLEYP, et al.Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors[J]Nucl Med Biol, 2000, 27( 8): 757-762.
doi: 10.1016/s0969-8051(00)00152-9
|
18 |
LAHDENPOHJAS, RAJALAN A, HELINJ S, et al.Ruthenium-mediated 18F-fluorination and preclinical evaluation of a new CB1 receptor imaging agent [18F]FPATPP[J]ACS Chem Neurosci, 2020, 11( 13): 2009-2018.
doi: 10.1021/acschemneuro.0c00313
|
19 |
WONGD F, KUWABARAH, HORTIA G, et al.Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR[J]Neuroimage, 2010, 52( 4): 1505-1513.
doi: 10.1016/j.neuroimage.2010.04.034
|
20 |
TSUJIKAWAT, ZOGHBIS S, HONGJ, et al.In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors[J]Neuroimage, 2014, 733-741.
doi: 10.1016/j.neuroimage.2013.09.043
|
21 |
HORTI A G, FAN H, KUWABARA H et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors[J]. J Nucl Med, 2006, 47: 1689-1696
|
22 |
RANGANATHANM, CORTES-BRIONESJ, RADHAKRISHNANR, et al.Reduced brain cannabinoid receptor availability in schizophrenia[J]Biol Psychiatry, 2016, 79( 12): 997-1005.
doi: 10.1016/j.biopsych.2015.08.021
|
23 |
NEUMEISTERA, NORMANDINM D, PIETRZAKR H, et al.Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study[J]Mol Psychiatry, 2013, 18( 9): 1034-1040.
doi: 10.1038/mp.2013.61
|
24 |
D’SOUZAD C, CORTES-BRIONESJ A, RANGANATHANM, et al.Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis[J]Biol Psychiatry Cogn Neurosci Neuroimaging, 2016, 1( 1): 60-67.
doi: 10.1016/j.bpsc.2015.09.008
|
25 |
CASTEELSC, KOOLEM, CELENS, et al.Preclinical evaluation and quantification of [18F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain[J]Eur J Nucl Med Mol Imaging, 2012, 39( 9): 1467-1477.
doi: 10.1007/s00259-012-2163-3
|
26 |
AHMADR, GOFFINK, VAN DEN STOCKJ, et al.In vivo type 1 cannabinoid receptor availability in Alzheimer’s disease[J]Eur Neuropsychopharmacol, 2014, 24( 2): 242-250.
doi: 10.1016/j.euroneuro.2013.10.002
|
27 |
CECCARINIJ, CASTEELSC, AHMADR, et al.Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease[J]Eur J Nucl Med Mol Imaging, 2019, 46( 11): 2348-2357.
doi: 10.1007/s00259-019-04445-x
|
28 |
CASTEELSC, VANDEPUTTEC, RANGARAJANJ R, et al.Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease[J]Exp Neurol, 2011, 229( 2): 440-449.
doi: 10.1016/j.expneurol.2011.03.014
|
29 |
OOMSM, RIETJENSR, RANGARAJANJ R, et al.Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice[J]Neurobiol Aging, 2014, 35( 12): 2858-2869.
doi: 10.1016/j.neurobiolaging.2014.06.010
|
30 |
CECCARINIJ, DE HERTM, VAN WINKELR, et al.Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia[J]Neuroimage, 2013, 304-312.
doi: 10.1016/j.neuroimage.2013.04.052
|
31 |
CECCARINIJ, KUEPPERR, KEMELSD, et al.[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users[J]Addict Biol, 2015, 20( 2): 357-367.
doi: 10.1111/adb.12116
|
32 |
TERRYG E, HIRVONENJ, LIOWJ S, et al.Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands[J]J Nucl Med, 2010, 51( 1): 112-120.
doi: 10.2967/jnumed.109.067074
|
33 |
TAKKINENJ S, LóPEZ-PICóNF R, KIRJAVAINENA K, et al.[18F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer’s disease[J]Neurobiol Aging, 2018, 199-208.
doi: 10.1016/j.neurobiolaging.2018.05.013
|
34 |
BORGANF, LAURIKAINENH, VERONESEM, et al.In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis[J]JAMA Psychiatry, 2019, 76( 10): 1074-1084.
doi: 10.1001/jamapsychiatry.2019.1427
|
35 |
HIRVONENJ, GOODWINR S, LIC T, et al.Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers[J]Mol Psychiatry, 2012, 17( 6): 642-649.
doi: 10.1038/mp.2011.82
|
36 |
TERRYG E, LIOWJ S, ZOGHBIS S, et al.Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand[J]Neuroimage, 2009, 48( 2): 362-370.
doi: 10.1016/j.neuroimage.2009.06.059
|
37 |
HODSONR. Alzheimer’s disease[J]Nature, 2018, 559( 7715): S1.
doi: 10.1038/d41586-018-05717-6
|
38 |
POEWEW, SEPPIK, TANNERC M, et al.Parkinson disease[J]Nat Rev Dis Primers, 2017, 3( 1): 17013.
doi: 10.1038/nrdp.2017.13
|
39 |
CASTEELSC, LAUWERSE, BAITARA, et al.In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson’s disease[J]Brain Res, 2010, 153-162.
doi: 10.1016/j.brainres.2009.12.026
|
40 |
VAN LAEREK, CASTEELSC, LUNSKENSS, et al.Regional changes in type 1 cannabinoid receptor availability in Parkinson’s disease in vivo[J]Neurobiol Aging, 2012, 33( 3): 620.e1-620.e8.
doi: 10.1016/j.neurobiolaging.2011.02.009
|
41 |
CARONN S, DORSEYE R, HAYDENM R. Therapeutic approaches to Huntington disease: from the bench to the clinic[J]Nat Rev Drug Discov, 2018, 17( 10): 729-750.
doi: 10.1038/nrd.2018.133
|
42 |
DOWIEM J, BRADSHAWH B, HOWARDM L, et al.Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington’s disease[J]Neuroscience, 2009, 163( 1): 456-465.
doi: 10.1016/j.neuroscience.2009.06.014
|
43 |
VAN LAEREK, CASTEELSC, DHOLLANDERI, et al.Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo[J]J Nucl Med, 2010, 51( 9): 1413-1417.
doi: 10.2967/jnumed.110.077156
|
44 |
CECCARINIJ, AHMADR, VAN DE VLIETL, et al.Behavioral symptoms in premanifest huntington disease correlate with reduced frontal CB1 R levels[J]J Nucl Med, 2019, 60( 1): 115-121.
doi: 10.2967/jnumed.118.210393
|
45 |
MARDERS R, CANNONT D. Schizophrenia[J]N Engl J Med, 2019, 381( 18): 1753-1761.
doi: 10.1056/NEJMra1808803
|
46 |
SHERIFM, RADHAKRISHNANR, D’SOUZAD C, et al.Human laboratory studies on cannabinoids and psychosis[J]Biol Psychiatry, 2016, 79( 7): 526-538.
doi: 10.1016/j.biopsych.2016.01.011
|
47 |
BORGANF, O’DALYO, VERONESEM, et al.The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study[J]Mol Psychiatry, 2019,
doi: 10.1038/s41380-019-0619-6
|
48 |
COHENK, WEIZMANA, WEINSTEINA. Modulatory effects of cannabinoids on brain neurotransmission[J]Eur J Neurosci, 2019, 50( 3): 2322-2345.
doi: 10.1111/ejn.14407
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|